ID
36687
Beschreibung
Immunosenescence and Hepatitis B Virus (HBV) Vaccine Efficacy in Chronic Renal Disease Patient; ODM derived from: https://clinicaltrials.gov/show/NCT02375711 Brief Summary: The aim of this study is to investigate the role of immunosenescence in the HBV vaccination response in patients with renal insufficiency. Detailed Description: The risk of infection with hepatitis B during exposure to blood is high (30% against 1.8% for Hepatitis C Virus and HIV 1%) and dialysis patients are a population at risk. Vaccination against this virus, which is very effective in the general population (vaccine response: 90 to 95%), is highly recommended in dialysis patients. However, numerous studies have shown that HBV vaccination was less effective in patients with chronic renal disease than in the general population. The reasons for low vaccine response are poorly understood. However, recent data suggest that renal failure could induce accelerated immunosenescence. The aging of the immune system, or immunosenescence, is a complex and profound phenomenon of the immune system during life. The gradual reduction of the generation of naive T cells in the thymus is the major cause of immunosenescence. But this process is also associated with an accumulation of lymphocytes at the end of differentiation. In this context, the decrease in vaccine response and increased infections in renal insufficiency might be correlated, as in the elderly population, with the aging of the immune system. The aim of this study is to investigate the role of immunosenescence in the HBV vaccination response in patients with renal insufficiency. Vaccination against HBV is not performed for the purposes of the study, but due to the existing vaccine indication for the subject. Included patients receive vaccination as routine care according to the recommendations and the vaccination schedule recommended by the Health Authority.
Link
https://clinicaltrials.gov/show/NCT02375711
Stichworte
Versionen (2)
- 15.01.19 15.01.19 -
- 01.06.19 01.06.19 -
Rechteinhaber
Centre Hospitalier Universitaire de Besancon
Hochgeladen am
1. Juni 2019
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
HBV Vaccine in Chronic Renal Disease NCT02375711
Eligibility Criteria
- StudyEvent: Eligibility
Beschreibung
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Beschreibung
Hepatitis B status
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C3714514
- UMLS CUI [1,2]
- C0019163
- UMLS CUI [2,1]
- C0474232
- UMLS CUI [2,2]
- C0262926
Beschreibung
Psychosis
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0033975
Beschreibung
Immosuppresive Therapy
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0021079
- UMLS CUI [1,2]
- C0262926
Beschreibung
Infection or Neoplasms
Datentyp
boolean
Alias
- UMLS CUI [1]
- C3714514
- UMLS CUI [2]
- C0006826
Ähnliche Modelle
Eligibility Criteria
- StudyEvent: Eligibility
C0474232 (UMLS CUI [1,2])
C0373595 (UMLS CUI [1,2])
C0474232 (UMLS CUI [1,2])
C0205160 (UMLS CUI [1,2])
C1285529 (UMLS CUI [1,2])
C2603343 (UMLS CUI [1,3])
C2347858 (UMLS CUI [1,2])
C2347026 (UMLS CUI [1,3])
C0035168 (UMLS CUI [1,4])
C0019163 (UMLS CUI [1,2])
C0474232 (UMLS CUI [2,1])
C0262926 (UMLS CUI [2,2])
C0262926 (UMLS CUI [1,2])
C0006826 (UMLS CUI [2])